2012
How Do Perceptions About Cessation Outcomes Moderate the Effectiveness of a Gain-Framed Smoking Cessation Telephone Counseling Intervention?
Latimer-Cheung AE, Fucito LM, Carlin-Menter S, Rodriguez J, Raymond L, Salovey P, Makuch R, Cummings KM, Toll BA. How Do Perceptions About Cessation Outcomes Moderate the Effectiveness of a Gain-Framed Smoking Cessation Telephone Counseling Intervention? Journal Of Health Communication 2012, 17: 1081-1098. PMID: 22765277, PMCID: PMC3644974, DOI: 10.1080/10810730.2012.665420.Peer-Reviewed Original ResearchConceptsState quitlineSmoking cessation counselingTelephone counseling interventionSmoking cessation messagesCessation counselingOutcome expectanciesSmoking statusSmoking cessationCessation messagesQuit statusHealth messagesSecondary analysisSmokers' beliefsCare messagesQuitlineIndividual perceptionsCounseling conditionCounseling interventionPreventionMenPositive outcome expectanciesInterventionOutcomesExpectancyIndividual differences
2010
Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: A randomized trial
Toll BA, White M, Wu R, Meandzija B, Jatlow P, Makuch R, O’Malley S. Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: A randomized trial. Drug And Alcohol Dependence 2010, 111: 200-206. PMID: 20542391, PMCID: PMC3771701, DOI: 10.1016/j.drugalcdep.2010.04.015.Peer-Reviewed Original ResearchConceptsWeight gainSmoking cessationPoint prevalence smoking abstinence ratePre-specified primary outcomesLow-dose naltrexoneOpen-label therapySmoking abstinence ratesPoint prevalence abstinenceReduced weight gainNaltrexone augmentationPlacebo groupNicotine replacementPrimary outcomeQuit dateAbstinence ratesLabel therapyNicotine patchBehavioral counselingNaltrexoneAbstinent participantsSmokersWeight concernsWeeksCessationLower rates
2009
GABAA‐benzodiazepine receptor availability in smokers and nonsmokers: Relationship to subsyndromal anxiety and depression
Esterlis I, Cosgrove KP, Batis JC, Bois F, Kloczynski TA, Stiklus SM, Perry E, Tamagnan GD, Seibyl JP, Makuch R, Krishnan‐Sarin S, O'Malley S, Staley JK. GABAA‐benzodiazepine receptor availability in smokers and nonsmokers: Relationship to subsyndromal anxiety and depression. Synapse 2009, 63: 1089-1099. PMID: 19642218, PMCID: PMC2778224, DOI: 10.1002/syn.20688.Peer-Reviewed Original ResearchConceptsSpielberger State-Trait Anxiety IndexState-Trait Anxiety IndexDepressive symptomsSubsyndromal anxietyAnxiety symptomsPain toleranceReceptor availabilityAbstinent tobacco smokersSex-matched nonsmokersSingle photon emissionPain symptomsHealthy ageSmoking statusTobacco smokersSubsyndromal depressionAbstinent smokersVulnerable smokersCold pressor taskNonsmokersGamma-aminobutyricEpidemiology ScaleSmokersAcute abstinenceBrain areasSymptoms
1980
Smoking abstinence and small cell lung cancer survival. An association.
Johnston-Early A, Cohen M, Minna J, Paxton L, Fossieck B, Ihde D, Bunn P, Matthews M, Makuch R. Smoking abstinence and small cell lung cancer survival. An association. JAMA 1980, 244: 2175-9. PMID: 6252357, DOI: 10.1001/jama.244.19.2175.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerCell lung cancerSS patientsLung cancerCell lung cancer survivalThymosin fraction V.Lung cancer survivalDiscontinuation of smokingStart of treatmentContinuation of smokingSurvival benefitCigarette smokingPoor prognosisPrognostic implicationsCancer survivalSurvival differencesRadiation therapyBetter survivalPatientsSmokingBeneficial effectsS groupDiagnosisSurvivalTherapy
1979
EFFECTS OF THYMOSIN IN VITRO IN CANCER PATIENTS AND CORRELATION WITH CLINICAL COURSE AFTER THYMOSIN IMMUNOTHERAPY
Chretien P, Lipson S, Makuch R, Kenady D, Cohen M. EFFECTS OF THYMOSIN IN VITRO IN CANCER PATIENTS AND CORRELATION WITH CLINICAL COURSE AFTER THYMOSIN IMMUNOTHERAPY. Annals Of The New York Academy Of Sciences 1979, 332: 135-147. PMID: 316979, DOI: 10.1111/j.1749-6632.1979.tb47107.x.Peer-Reviewed Original Research